A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
Reason given: Sponsor decision
Key facts
- Where
- Aurora, Los Angeles, Louisville, Nashville, New York, Pittsburgh, and Seattle, United StatesSee the 7 sites
- Phase
- Phase 1
Where in United States
- University of Colorado Health Sciences CenterAurora, United StatesNo longer taking part
- University of Southern California Norris Comprehensive Cancer CenterLos Angeles, United StatesNo longer taking part
- Norton Cancer InstituteLouisville, United StatesNo longer taking part
- Sarah Cannon Research InstituteNashville, United StatesNo longer taking part
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Blavatnik Family-Chelsea Medical CenterNew York, United StatesNo longer taking part
- UPMC Hillman Cancer CenterPittsburgh, United StatesNo longer taking part
- University of WashingtonSeattle, United StatesNo longer taking part
Trial details
- Who runs it
- Zymeworks BC Inc.
- Trial code
- NCT06523803
- Record updated
- 21 October 2025
- Original description
This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced [inoperable] and/or metastatic) mesothelin-expressing cancers.Read full original descriptionShow less
A Phase 1, Open-label, Multicenter Study of ZW171 in Participants With Advanced or Metastatic Ovarian Cancer, Non-small Cell Lung Cancer (NSCLC), and Other Mesothelin Expressing Cancers
This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced [inoperable] and/or metastatic) mesothelin-expressing cancers.
Inclusion: Pathologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable) and/or metastatic disease. Cancers that are refractory to all available standard of care (SOC) treatment, cancers for which no SOC treatment is available, or the participant cannot tolerate or refuses SOC therapy; An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1; Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction ≥ 50% as determined by either echocardiogram or multigated acquisition scan; Adequate organ function.
Exclusion: Undergone prior allogenic tissue (e.g., hematopoietic stem cell) or solid organ transplantation within the last 5 years; Advanced/metastatic, symptomatic, visceral spread, at risk of life-threatening complications in the short-term (including participants with massive uncontrolled effusion [pleural, pericardial], pulmonary lymphangitis, active unresolved bowel obstruction, massive ascites [requiring paracentesis >2 times within 2 weeks prior to the first dose], and over 50% liver involvement); Known additional malignancy that is progressing or that has required active treatment; Ongoing, clinically significant toxicity (Grade ≥ 2) associated with prior cancer therapies, with the exception of alopecia; Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of participants with Gilbert's Syndrome, asymptomatic gall stones, liver metastases, or stable chronic liver disease per investigator assessment); Active or recurrent clinically significant autoimmune disease requiring systemic high-dose corticosteroids or immunosuppressive drugs.